XBiotech Inc.
XBIT
$2.42
-$0.02-0.82%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -75.71% | 354.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -78.91% | 392.06% | |||
| Operating Income | 78.91% | -392.06% | |||
| Income Before Tax | 79.65% | -354.05% | |||
| Income Tax Expenses | -35.53% | -25.49% | |||
| Earnings from Continuing Operations | 79.53% | -347.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 79.53% | -347.60% | |||
| EBIT | 78.91% | -392.06% | |||
| EBITDA | 79.77% | -422.72% | |||
| EPS Basic | 79.53% | -347.54% | |||
| Normalized Basic EPS | 80.08% | -363.42% | |||
| EPS Diluted | 79.53% | -347.54% | |||
| Normalized Diluted EPS | 80.08% | -363.42% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||